| 31/03/26 | 07:00:07 | 31 Mar 2026 | | Interim Results for six months ended 31 Dec 2025 |
| 12/03/26 | 07:00:12 | 12 Mar 2026 | | PDMR Dealings & Shareholding Update |
| 04/03/26 | 07:00:11 | 4 Mar 2026 | | Positive Biomarker Results from PROTECT Trial |
| 26/02/26 | 07:00:11 | 26 Feb 2026 | | Allergy Therapeutics presents progress at AAAAI |
| 23/02/26 | 07:51:18 | 23 Feb 2026 | | Update on funding and total voting rights |
| 30/01/26 | 08:22:49 | 30 Jan 2026 | | Chief Strategy Officer and Board appointments |
| 29/01/26 | 14:13:11 | 29 Jan 2026 | | Result of Annual General Meeting |
| 28/01/26 | 16:48:32 | 28 Jan 2026 | | Grant of Options under Long Term Incentive Scheme |
| 19/01/26 | 07:00:05 | 19 Jan 2026 | | Half Year Trading Update |
| 06/01/26 | 07:00:08 | 6 Jan 2026 | | Notice of 2025 Annual General Meeting |
| 29/12/25 | 13:07:28 | 29 Dec 2025 | | Results of General Meeting |
| 16/12/25 | 07:00:08 | 16 Dec 2025 | | Grassmuno® marketing authorisation in Germany |
| 12/12/25 | 07:00:08 | 12 Dec 2025 | | Authority for allotment of New Shares |
| 11/12/25 | 07:00:08 | 11 Dec 2025 | | Prelim Results and publication of Annual Report |
| 09/12/25 | 07:00:10 | 9 Dec 2025 | | Primary Safety Endpoint Met in PROTECT trial |
| 06/11/25 | 07:22:37 | 6 Nov 2025 | | Company to Evaluate Dual Listing on HKEX |
| 30/10/25 | 07:00:10 | 30 Oct 2025 | | G308 Phase III Year 2 Patient Screening Starts |
| 29/10/25 | 07:00:05 | 29 Oct 2025 | | Warrant Exercise and Paydown of Debt |
| 16/10/25 | 07:00:09 | 16 Oct 2025 | | Further progress in Phase I/IIa PROTECT trial |
| 31/07/25 | 07:00:17 | 31 Jul 2025 | | Grass MATA MPL Publications in Allergy Journal |
| 21/07/25 | 07:00:06 | 21 Jul 2025 | | Trading update for the year ended 30 June 2025 |
| 11/07/25 | 07:00:08 | 11 Jul 2025 | | PDMR Dealings |
| 13/06/25 | 07:00:12 | 13 Jun 2025 | | Allergy Therapeutics presents findings at EAACI |
| 10/06/25 | 07:04:59 | 10 Jun 2025 | | EAACI Early Career Research Award |
| 31/03/25 | 07:00:12 | 31 Mar 2025 | | Interim Results for six months ended 31 Dec 2024 |
| 27/03/25 | 07:00:06 | 27 Mar 2025 | | Advancement to final phase of PROTECT trial |
| 03/03/25 | 07:00:11 | 3 Mar 2025 | | New Executive Long Term Incentive Awards |
| 27/02/25 | 07:00:14 | 27 Feb 2025 | | Presentations at 2025 AAAAI / WAO Joint Congress |
| 17/02/25 | 07:00:04 | 17 Feb 2025 | | Grass MATA MPL Phase III data published in Allergy |
| 14/02/25 | 07:00:07 | 14 Feb 2025 | | Grant of Options |
| 28/01/25 | 07:00:03 | 28 Jan 2025 | | Half Year Trading update |
| 22/01/25 | 07:00:05 | 22 Jan 2025 | | PDMR Dealing and Total Voting Rights |
| 15/01/25 | 07:00:06 | 15 Jan 2025 | | Director/PDMR Shareholding |
| 19/12/24 | 13:41:42 | 19 Dec 2024 | | Exercise of Options and Total Voting Rights |
| 17/12/24 | 16:19:15 | 17 Dec 2024 | | Block Listing Interim Review |
| 16/12/24 | 15:33:58 | 16 Dec 2024 | | Result of Annual General Meeting |
| 04/12/24 | 07:00:04 | 4 Dec 2024 | | Positive Interim Data from PROTECT Trial |
| 27/11/24 | 07:00:03 | 27 Nov 2024 | | First Patient Dosed in G308 Paediatric Trial |
| 25/11/24 | 07:00:03 | 25 Nov 2024 | | Submission of MAA for Grass MATA MPL |
| 21/11/24 | 07:00:11 | 21 Nov 2024 | | Notice of 2024 Annual General Meeting |
| 06/11/24 | 07:00:06 | 6 Nov 2024 | | Audited Preliminary Results 2024 |
| 21/10/24 | 07:00:01 | 21 Oct 2024 | | Commencement of Phase III Paediatric Trial |
| 16/10/24 | 07:00:04 | 16 Oct 2024 | | Update on funding |
| 01/10/24 | 07:00:08 | 1 Oct 2024 | | Update on funding and preliminary results |
| 17/09/24 | 07:00:02 | 17 Sept 2024 | | Progression of patient cohorts in PROTECT Trial |
| 27/08/24 | 07:00:12 | 27 Aug 2024 | | Update on funding |
| 22/07/24 | 07:01:00 | 22 Jul 2024 | | Trading update for the year ended 30 June 2024 |
| 22/07/24 | 07:00:10 | 22 Jul 2024 | | Appointment of Nominated Adviser and Sole Broker |
| 04/07/24 | 14:22:06 | 4 Jul 2024 | | Launch of new Company Long Term Incentive Plan |
| 27/06/24 | 07:00:14 | 27 Jun 2024 | | Appointment of Non-Executive Director |
